The U.S. Food and Drug Administration on Friday issued an Early Alert about a potentially high-risk issue with certain vascular guidewires that Heraeus Medical Components, doing business as Heraeus Medevio, has asked customers to remove from use and sale.
The FDA said Heraeus sent a voluntary medical device recall letter on Nov. 4-5 recommending that affected guidewires be taken out of service. The agency said the company reported a potential product quality issue in which the hydrophilic coating on some lots can swell inconsistently when exposed to saline and clump, most often on the distal coil. According to Heraeus, clumping can raise the chance of coating flaking, displacement, or detachment, which could release particles into a patient’s bloodstream and lead to a thromboembolic event depending on the size and amount of material released.
Affected devices include Navilyst Vascular Guidewire models H965457461 and H965457471; Spectrum Vascular Guidewire models H965457461 and H965457471; and Arrow Marked Guidewire models PW-18080-HN and PW-16130-HN, the FDA said. The agency said the risks from hydrophilic polymer embolization are highest if material reaches the heart, lungs, brain, kidneys, vascular grafts, or areas with poor peripheral circulation. Reported outcomes range from no symptoms to vascular blockage, ischemia, infarction, hemorrhage, stroke, organ failure, multiorgan failure, and death, according to the alert.
The FDA stated that Heraeus had not reported any serious injuries or deaths linked to this issue as of Nov. 5. The affected guidewires are nickel titanium devices with a radiopaque metallic coil tip and a hydrophilic coating. They are indicated for percutaneous entry of peripheral vessels using the Seldinger Technique and are not indicated for use in the coronary or cerebral vasculature, the agency said.
Heraeus advised customers to review inventory and distribution records, immediately stop distribution, quarantine affected products, ensure all relevant facilities and staff are informed, and notify downstream customers to stop use and quarantine affected stock. The FDA said users should cease use and distribution and quarantine affected lots.
The FDA said it is reviewing information about this potentially high-risk device issue and will update its web page as significant new information becomes available. The agency said patients and health care workers can file reports of side effects or device quality issues through MedWatch, the FDA’s Safety Information and Adverse Event Reporting Program. Customers in the United States with questions can contact Heraeus Medevio at MedevioRegulatoryAffairs@heraeus.com or 612-325-2003.
Earlier this week, the FDA issued other Early Alerts, including for Outset Medical Tablo power cords and B. Braun’s Caresite Micro Luer Access Device, as previously reported.